ArticleMycotoxin research2020
Ochratoxin A in human blood plasma samples from apparently healthy volunteers in Nanjing, China.
Article in Mycotoxin research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Urinary Biomonitoring of Mycotoxins in Spanish Adults: Predictors of Exposure and Health Risk Evaluation.Toxics · 2025Article
- Multiple mycotoxin exposure assessment through human biomonitoring in an esophageal cancer case-control study in the Arsi-Bale districts of Oromia region of Ethiopia.International journal of hygiene and environmental health · 2025Article
- Biomonitoring of ochratoxin A, 2'R-ochratoxin A and citrinin in human blood serum from Switzerland.Mycotoxin research · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
This study was conducted to investigate the exposure to ochratoxin A (OTA) of populations living in Nanjing, China. Plasma samples were collected from 147 healthy adults (age 18-63 years) and analyzed for OTA by a reliable and sensitive ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method (limit of detection 0.04 ng/mL). After enzymatic hydrolysis by β-glucuronidase/arylsulfatase, OTA was detected in 80.9% plasma samples with mean concentration of 0.26 ± 0.59 ng/mL (range 0.04-6.59 ng/mL). The estimated daily intakes of OTA based on plasma concentrations (mean 0.51 ng/kg bw/day, max 12.99 ng/kg bw/day) were lower than the tolerable daily intake published by European Food Safety Authority (EFSA) or Joint FAO/WHO Expert Committee on Food Additives (JFECFA) indicative of rare risks related to the OTA exposure in the investigated area. This study provides a valuable insight on human exposure to OTA in China. Further studies in children and elder people and in adult cohorts from other regions are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.